Successful Treatment of Atopic Dermatitis with Dupilumab in a Patient with Non-Hodgkin’s Lymphoma
DOI:
https://doi.org/10.2340/actadv.v101.224Keywords:
atopic dermatitis, dupilumab, non-Hodgkin’s lymphomaAbstract
Abstract is missing (Short communication)
Downloads
References
Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 2020; 82: 377-388.
https://doi.org/10.1016/j.jaad.2019.07.074 DOI: https://doi.org/10.1016/j.jaad.2019.07.074
Chun PIF, Lehman H. Current and future monoclonal antibodies in the treatment of atopic dermatitis. Clin Rev Allergy Immunol 2020; 59: 208-219.
https://doi.org/10.1007/s12016-020-08802-9 DOI: https://doi.org/10.1007/s12016-020-08802-9
Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M. Potential risks related to modulating interleukin-13 and interleukin-4 signalling: a systematic review. Drug Saf 2018; 41: 489-509.
https://doi.org/10.1007/s40264-017-0636-9 DOI: https://doi.org/10.1007/s40264-017-0636-9
Fowler E, Rosen J, Lev-Tov H, Yosipovitch G. Two cancer patients receiving dupilumab for treatment of atopic dermatitis. Acta Derm Venereol 2019; 99: 899-900.
https://doi.org/10.2340/00015555-3201 DOI: https://doi.org/10.2340/00015555-3201
Arellano FM, Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol 2009; 123: 1111-1116.
https://doi.org/10.1016/j.jaci.2009.02.028 DOI: https://doi.org/10.1016/j.jaci.2009.02.028
Francuzik W, Alexiou A, Worm M. Safety of dupilumab in patients with atopic dermatitis: expert opinion. Expert Opin Drug Saf 2021; 20: 997-1004.
https://doi.org/10.1080/14740338.2021.1939673 DOI: https://doi.org/10.1080/14740338.2021.1939673
Miyashiro D, Vivarelli AG, Goncalves F, Cury-Martins J, Sanches JA. Progression of mycosis fungoides after treatment with dupilumab: a case report. Dermatol Ther 2020; 33: e13880.
https://doi.org/10.1111/dth.13880 DOI: https://doi.org/10.1111/dth.13880
Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol 2020; 83: 197-199.
https://doi.org/10.1016/j.jaad.2020.03.050 DOI: https://doi.org/10.1016/j.jaad.2020.03.050
Sinha A, Velangi S, Natarajan S. Non-Hodgkin's lymphoma following treatment of atopic eczema with cyclosporin A. Acta Derm Venereol 2004; 84: 327-328.
https://doi.org/10.1080/00015550410025967 DOI: https://doi.org/10.1080/00015550410025967
Mansfield KE, Schmidt SAJ, Darvalics B, Mulick A, Abuabara K, Wong AYS, et al. Association between atopic eczema and cancer in England and Denmark. JAMA Dermatol 2020; 156: 1086-1097.
https://doi.org/10.1001/jamadermatol.2020.1948 DOI: https://doi.org/10.1001/jamadermatol.2020.1948
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 YunMi Qiu, Kamran Ali, HaiYue Lou, JingPeng Shan, Liming Wu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.